The Respiratory Effectiveness Group (REG) Summit, which took place on 28–29 June 2014, provided clinicians, general practitioners, pulmonologists, and representatives from the industry with the opportunity to discuss real-life effectiveness research in respiratory disease. This white paper presents research from studies identified of particular relevant to the asthma and COPD markets which revealed:
The potential benefits that Symbicort (budesonide/formoterol; AstraZeneca) may have over Spiriva.
The Value of add-on Spiriva therapy in asthma as Boehringer Ingelheim prepares to expand Spiriva's indications in the EU.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: